Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 13:13:3-6.
doi: 10.1016/j.ymgmr.2017.06.010. eCollection 2017 Dec.

Lipid profile in adult patients with Fabry disease - Ten-year follow up

Karolina M Stepien  1 , Chris J Hendriksz  1   2
Affiliations

Lipid profile in adult patients with Fabry disease - Ten-year follow up

Karolina M Stepien et al. Mol Genet Metab Rep. .

Abstract

Background: Fabry disease, an X-linked genetic condition, results from alpha-galactosidase deficiency and increased accumulation of glycosphingolipids in cardiovascular tissues. Clinical manifestation includes vasculature associated complications. Hyperlipidaemia is one of the cardiovascular risk factors however it has never been well defined in Fabry disease. Enzyme Replacement Therapy (ERT) is available but its effect on serum cholesterol is unknown. The aim of this project was to assess the influence of long-term ERT on lipid profile in a large cohort of adult patients with Fabry disease.

Methods: This was a retrospective analysis of lipid profile results. Patients with Fabry disease were on ERT for 10 years, were not treated with statins and had no severe renal impairment. All patients had lipid profile measured before ERT was commenced and 6, 12, 24, 36, 48, 60, 120 months later. Statistical analysis included ANOVA, Student t-test and descriptive statistics.

Results: Among 72 patients, 40 were females (median age 45; range 29-75), 32 males (median age 46; range 20-69). There was no significant difference in total cholesterol or HDL-cholesterol measured at baseline before ERT was commenced and 6, 12, 24, 36, 48, 60 and 120 months after ERT was commenced in 72 patients (ANOVA; P = 0.673 and P = 0.883, respectively). Female patients on ERT had higher mean HDL-cholesterol as compared to female patients with Fabry disease who were asymptomatic and not treated (P ≥ 0.05). Total cholesterol between treated and non-treated female patients was comparable. Female patients on ERT have higher total cholesterol and HDL-cholesterol when compared to lipid results in male patients on ERT. Total cholesterol/HDL-cholesterol ratio was low in female and male patients on ERT over 10 years.

Conclusion: Adult patients with Fabry disease have remarkably elevated HDL-cholesterol and as a result, elevated total cholesterol. It is possible that elevated HDL-cholesterol has a cardioprotective effect in patients with this condition. Long term ERT does not have a significant impact on lipid profile in female and male population with Fabry disease.

Keywords: Cholesterol; Enzyme replacement therapy; Fabry disease; HDL-cholesterol.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Desnick R.J., Ioannou Y.A., Eng M.E. a-Galactosidase A deficiency: Fabry disease. In: Scriver C.R., Beaudet A.L.S.W., Valle D., editors. The Metabolic and Molecular Bases of Inherited Disease. eighth ed. McGraw-Hill; New York: 2001. pp. 3733–3774.
    1. Moore D.F., Kaneski C.R., Askari H., Schiffmann R. The cerebral vasculopathy of Fabry disease. J. Neurol. Sci. 2007;257:258–263. - PubMed
    1. Schiffmann R. Fabry disease. Pharmacol. Ther. 2009;122:65–77. - PubMed
    1. Rolfs A., Bottcher T., Zschiesche M., Morris P., Winchester B., Bauer P., Walter U., Mix E., Lohr M., Harzer K., Strauss U., Pahnke J., Grossmann A., Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366:1794–1796. - PubMed
    1. Sessa A., Meroni M., Battini G., Maglio A., Brambilla P.L., Bertella M., Nebuloni M., Pallotti F., Giordano F., Bertagnolio B., Tosoni A. Renal pathological changes in Fabry disease. J. Inherit. Metab. Dis. 2001;24(Suppl. 2):66–70. - PubMed